# Impact of Short‐Term Insulin Pump Therapy on Cardiometabolic Index in Patients With Newly Diagnosed Type 2 Diabetes Mellitus

## TL;DR

Short-term insulin pump therapy in new type 2 diabetes patients improves blood sugar and insulin resistance while lowering a key cardiometabolic index.

## Contribution

Demonstrates the impact of short-term CSII on cardiometabolic index and its correlation with insulin resistance in newly diagnosed T2DM patients.

## Key findings

- Short-term CSII treatment significantly reduced cardiometabolic index (CMI) in T2DM patients.
- CMI was positively correlated with insulin resistance (HOMA-IR) and negatively with β-cell function (HOMA-β).
- CMI was independently associated with fasting C-peptide levels before and after treatment.

## Abstract

This study aims to investigate the changes in cardiometabolic index (CMI) levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients before and after undergoing short‐term continuous subcutaneous insulin infusion (CSII) intensive treatment and analyse its correlation with insulin resistance.

This study retrospectively collected data from 604 patients who were initially diagnosed with T2DM and received short‐term CSII treatment during their hospitalisation in the Endocrinology Department of the Affiliated Hospital of Jiangsu University. Clinical data, blood glucose, insulin, C‐peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.

Short‐term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β‐cell function in T2DM patients, while downregulating the CMI index (p = 0.002). Correlation analysis showed a positive correlation between CMI and HOMA‐IR (p < 0.001) and a negative correlation between CMI and HOMA‐β (p = 0.008). Stepwise linear regression model analysis revealed that CMI was independently associated with fasting C‐peptide (FCP) before treatment (β = 0.291, p < 0.001); after treatment, CMI was associated with FCP (β = 0.160, p < 0.001) and HOMA‐IR (β = 0.159, p < 0.001).

After short‐term intensive CSII treatment, the CMI level in newly diagnosed T2DM patients significantly decreased, indicating that intensive CSII treatment may have certain significance in improving cardiometabolic function.

The study reveals that CMI levels significantly decrease after short‐term CSII therapy in T2DM, with CMI positively correlated with insulin resistance, indicating the therapy's significance in improving patients' cardiometabolic function.